Literature DB >> 1728675

The economics of femorocrural reconstruction for critical leg ischemia with and without autologous vein.

N J Cheshire1, J H Wolfe, M A Noone, L Davies, M Drummond.   

Abstract

It is well established that primary arterial reconstruction, even to crural vessels, is cheaper than amputation. Reintervention increases expenditure and may produce mean costs exceeding those of primary amputation. Furthermore, secondary amputation may eventually become necessary. Femorocrural grafts have the highest average "reconstruction policy" cost (i.e., primary procedure and all further operations necessary during follow-up). We must therefore seek support for this potentially expensive form of treatment. In conjunction with health economists we have compared the average policy cost of 130 reconstructions with grafts exceeding 70 cm in length (89 vein grafts, 41 polytetrafluoroethylene grafts with a distal vein collar) with 67 vascular amputations, at mean follow-up of 3 years. One-month mortality rate after reconstruction was less than 1% but was 10% after amputation. At 3 years, however, 20% of both groups were dead. Overall 3-year patency is 65% (72% for vein grafts, 48% for polytetrafluoroethylene grafts). Ninety-seven percent of irreversible graft occlusions resulted in amputation in these patients. After autologous vein grafting reintervention, our follow-up showed increased mean costs from $6898 to $15,024 per patient. After prosthetic grafting, the higher reintervention rate increased from $6898 to $20,416. These mean costs remained less than amputation, reintervention, and additional mobility costs, which amounted to a mean of $21,726 per patient. Important differences in outcome were observed: 70% of patients undergoing amputation were confined to the home compared with only 9% of patients undergoing reconstruction; 30% of patients undergoing amputation were confined to bed or had to use a wheelchair compared with 1% of patients undergoing reconstruction.

Entities:  

Mesh:

Year:  1992        PMID: 1728675     DOI: 10.1067/mva.1992.33676

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  10 in total

Review 1.  Cost-effective management of diabetic foot ulcers. A review.

Authors:  G Ragnarson-Tennvall; J Apelqvist
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

Review 2.  Non-cardiac vascular disease.

Authors:  Thomas W G Carrell; John H N Wolfe
Journal:  Heart       Date:  2005-02       Impact factor: 5.994

3.  Inextricably linked: training and service in peripheral vascular surgery.

Authors:  J Wolfe; R Wood; L de Cossart
Journal:  Ann R Coll Surg Engl       Date:  1997-09       Impact factor: 1.891

4.  Vein graft surveillance: is the case proven?

Authors:  D K Beattie; R M Greenhalgh; A H Davies
Journal:  Ann R Coll Surg Engl       Date:  1997-01       Impact factor: 1.891

5.  Femorotibial bypass: the learning curve.

Authors:  M G Wyatt; V F Kernick; H Clark; W B Campbell
Journal:  Ann R Coll Surg Engl       Date:  1995-11       Impact factor: 1.891

6.  Cost effectiveness league tables.

Authors:  J Michaels
Journal:  BMJ       Date:  1993-04-17

7.  Relation between rates of leg amputation and distal arterial reconstructive surgery. Oxford Regional Vascular Audit Group.

Authors:  J A Michaels; P Rutter; J Collin; F M Legg; R B Galland
Journal:  BMJ       Date:  1994-12-03

Review 8.  [Patient assessments of quality of life following bypass for chronic critical limb ischaemia].

Authors:  M Engelhardt; W A Wohlgemuth; C Willy; M Tannheimer; K D Wölfle
Journal:  Chirurg       Date:  2009-04       Impact factor: 0.955

9.  Critical limb ischaemia in a diabetic population from an Asian Centre: angiographic pattern of disease and 3-year limb salvage rate with percutaneous angioplasty as first line of treatment.

Authors:  M Tan; U Pua; D E S Wong; S J Punamiya; G C Chua; N Teo
Journal:  Biomed Imaging Interv J       Date:  2010-10-01

Review 10.  A review of the pathophysiology and potential biomarkers for peripheral artery disease.

Authors:  Smriti Murali Krishna; Joseph V Moxon; Jonathan Golledge
Journal:  Int J Mol Sci       Date:  2015-05-18       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.